Analyst Price Target is $36.23
▲ +105.62% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Allogene Therapeutics in the last 3 months. The average price target is $36.23, with a high forecast of $53.00 and a low forecast of $18.00. The average price target represents a 105.62% upside from the last price of $17.62.
Current Consensus is
The current consensus among 16 contributing investment analysts is to buy stock in Allogene Therapeutics. This Buy consensus rating has held steady for over two years.
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.